Giuseppe Claudio Viscomi,Paola Maffei,Giuseppe Bottoni,Maria Grimaldi
申请号：
US13238739
公开号：
US20120245192A1
申请日:
2011.09.21
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form β, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.
